ingrezza overcom headwind
report financi pipelin updat spotlight
ingrezza post beat come vs con
estimate management plan expand sale forc given strong demand ahead top-line
data tourett fda mtg around snda ha
number catalyst incl data ts elagolix pdufa
ingrezza exce expect consecut note correctli predict
rev base proprietari doc survey work recal con conserv
flat q/q given pot payer hurdl medicar donut hole convers mg
bid lower price mg qd howev management note donut hole/plan reset account
season headwind less intern project trx
repres q/q step net rev per rx
driven primarili mg convers management think mostli complet
persist therapi saw slight declin attribut pt tx and/
skip dose rather full discontinu
management plan expand sale increas
sale forc current rep w/ new rep hire train deploy
management expect pick new acct across neuro psych alli hcp institut
acct commun mental health set
pipelin updat led expans ts prgm management reiter track
deliv top-line data pii/iii t-forc gold trial tourett syndrom ts ye
would trigger pot discuss w/ fda possibl file thereaft
also management initi t-forc platinum studi ingrezza ped ts pt
double-blind random pbo-control withdraw trial label possibl
phase iv studi request fda enrol begin data
toplin late poc data expect summer opicapon
nda track
financi report dilut ep vs estimate con
higher opex due one-tim expens incl one-tim
mileston payment result guidanc opex increas
prev driven plan comm expans
pt dcf-base risk includ clinic regulatori commerci
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
ingrezza launch tardiv dyskinesia pediatr
ingrezza peak sale risk-adj
elagolix success develop endometriosi
expect addit share gain ingrezza moderate-to-
sever mild tardiv dyskinesia ye
lead competitor austedo teva
model us approv elagolix endometriosi
uterin fibroid risk
opicapon approv us follow requir piii trial
model us approv opicapon risk
model us approv ingrezza pediatr tourett
syndrom risk discount
summer top-line data poc studi
ingrezza pediatr tourett syndrom de-risk
elagolix endometriosi uterin fibroid de-risk
opicapon approv us without requir piii
pipelin product success develop
ingrezza fail demonstr efficaci pediatr
elagolix fail demonstr efficaci endometriosi
opicapon approv us
pipelin product fail develop
expect pdufa date elagolix endometriosi
late full data t-forc gold trial pediatr
w/ fda discuss regulatori path snda
submiss ingrezza pediatr tourett syndrom
submiss opicapon nda parkinson diseas
late top-line data t-forc platinum withdraw studi
ingrezza pediatr tourett syndrom
base pro forma financi statement
page
pleas see import disclosur inform page report
reach pt base termin growth rate discount rate
valu neurocrin ingrezza elagolix acquir asset opicapon believ
ingrezza achiev domest probability-adjust sale
tardiv dyskinesia td tourett syndrom respect assum risk-discount
tourett syndrom
elagolix expect us launch partner buy cover ian
hillik model ex-u launch elagolix well believ elagolix
achiev domest probability-adjust sale
endometriosi uterin fibroid respect assum risk-discount
program note product market model
tier royalti sale tier royalti ex-u sale believ
opicapon achiev probability-adjust peak sale
fy manag guid increas oper expens
prev driven plan commerci expans support ingrezza
clinic failur compani
biotechnolog pharmaceut
develop treatment futur clinic failur lead delay approv
possibl discontinu program
regulatori failur fda could determin compani nda inadequ
could delay approv delay approv timelin could impact earn
commerci failur estim may reli success company/partn
receiv drug reimburs private/publ medic insur payer
financ risk may need rais addit fund support sg
activ current includ estim addit equiti rais howev
page
pleas see import disclosur inform page report
